Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Associations of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B With Cardiovascular Disease Occurrence in Adults: Korean Genome and Epidemiology Study

  • Shin Young Yun (Department of Laboratory Medicine, Yonsei University College of Medicine) ;
  • John Hoon Rim (Department of Laboratory Medicine, Yonsei University College of Medicine) ;
  • Hyein Kang (Department of Laboratory Medicine, Yonsei University College of Medicine) ;
  • Sang-Guk Lee (Department of Laboratory Medicine, Yonsei University College of Medicine) ;
  • Jong-Baeck Lim (Department of Laboratory Medicine, Yonsei University College of Medicine)
  • Received : 2022.04.23
  • Accepted : 2022.11.02
  • Published : 2023.05.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Despite the superiority of non-HDL cholesterol (non-HDL-C) and apolipoprotein B (ApoB) as lipid markers for atherosclerotic cardiovascular disease (ASCVD), these are only suitable as secondary markers. We compared LDL cholesterol (LDL-C), non-HDL-C, and ApoB concentrations with respect to the occurrence of cardiovascular disease in adults enrolled in the Korean Genome and Epidemiology Study (KoGES). Methods: We used information on age; sex; medical history; family history of ASCVD; current lipid-lowering therapy; current smoking status; and creatinine, total cholesterol, HDL-C, LDL-C, triglyceride, and ApoB concentrations from 5,872 KoGES participants without ASCVD. New ASCVD development was monitored during the 8-year follow-up period. Adjusted hazard ratios (aHRs) for ASCVD of LDL-C, non-HDL-C, and ApoB concentrations were calculated based on the multivariate Cox regression analyses. The participants were also grouped as low and high according to the median values for each lipid marker, and calculated aHRs of each group combined by two lipid makers. Results: ApoB showed the highest aHR per 1-SD for ASCVD (1.26; 95% confidence interval [CI], 1.11-1.43), followed by non-HDL-C (1.25; 95% CI, 1.11-1.41) and LDL-C (1.20; 95% CI, 1.06-1.37). The group with low LDL-C and high ApoB concentrations had a significantly higher aHR for ASCVD (1.61; 95% CI, 1.05-2.48) compared to the reference group values (low LDL-C and low ApoB concentrations). The aHR for the group with high LDL-C and low ApoB concentrations was not significant (1.30; 95% CI, 0.79-2.16). Conclusions: ApoB, non-HDL-C, and LDL-C are independent risk factors for ASCVD. Increases in the aHR per 1-SD for ASCVD were more strongly affected by ApoB, followed by non-HDL-C and LDL-C. Participants with low LDL-C and high ApoB concentrations showed increased ASCVD risk. For individuals with ASCVD risk factors, even those presenting normal LDL-C concentrations, measuring ApoB concentrations can provide useful information for better evaluation of ASCVD risk.

Keywords

Acknowledgement

This study was conducted with bioresources from National Biobank of Korea, the Korea Disease Control and Prevention Agency, Republic of Korea (KBN-2019-061).

References

  1. Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep 2012;14:1-10. https://doi.org/10.1007/s11883-011-0219-7
  2. Reith C and Armitage J. Management of residual risk after statin therapy. Atherosclerosis 2016;245:161-70. https://doi.org/10.1016/j.atherosclerosis.2015.12.018
  3. Shapiro MD and Fazio S. From lipids to inflammation: new approaches to reducing atherosclerotic risk. Circ Res 2016;118:732-49. https://doi.org/10.1161/CIRCRESAHA.115.306471
  4. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019;73:3168-209. https://doi.org/10.1016/j.jacc.2018.11.002
  5. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2020; 41:111-88. https://doi.org/10.1093/eurheartj/ehz455
  6. Verbeek R, Hovingh GK, Boekholdt SM. Non-high-density lipoprotein cholesterol: current status as cardiovascular marker. Curr Opin Lipidol 2015;26:502-10. https://doi.org/10.1097/MOL.0000000000000237
  7. Sniderman AD, Thanassoulis G, Glavinovic T, Navar AM, Pencina M, Catapano A, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol 2019;4:1287-95. https://doi.org/10.1001/jamacardio.2019.3780
  8. Cantey EP and Wilkins JT. Discordance between lipoprotein particle number and cholesterol content: an update. Curr Opin Endocrinol Diabetes Obes 2018;25:130-6. https://doi.org/10.1097/MED.0000000000000389
  9. Mora S. Advanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use. Circulation. 2009;119:2396-404. https://doi.org/10.1161/CIRCULATIONAHA.108.819359
  10. Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, et al. A meta-analysis of low-density lipoprotein cholesterol, nonhigh-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011;4:337-45. https://doi.org/10.1161/CIRCOUTCOMES.110.959247
  11. Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients. J Am Coll Cardiol 2021;77:1439-50. https://doi.org/10.1016/j.jacc.2021.01.027
  12. Thanassoulis G, Williams K, Ye K, Brook R, Couture P, Lawler PR, et al. Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials. J Am Heart Assoc 2014;3:e000759. https://doi.org/10.1161/JAHA.113.000759
  13. Kim Y, Han BG, KoGES Group. Cohort profile: the Korean Genome and Epidemiology Study (KoGES) consortium. Int J Epidemiol 2017;46:e20. https://doi.org/10.1093/ije/dyv316
  14. Nance R, Delaney J, McEvoy JW, Blaha MJ, Burke GL, Navas-Acien A, et al. Smoking intensity (pack/day) is a better measure than pack-years or smoking status for modeling cardiovascular disease outcomes. J Clin Epidemiol 2017;81:111-9. https://doi.org/10.1016/j.jclinepi.2016.09.010
  15. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000. https://doi.org/10.1001/jama.2009.1619
  16. Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, et al. Lipid-related markers and cardiovascular disease prediction. JAMA 2012;307:2499-506.
  17. Marston NA, Giugliano RP, Melloni GEM, Park JG, Morrill V, Blazing MA, et al. Association of apolipoprotein B–containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: distinguishing between particle concentration, type, and content. JAMA Cardiol 2022;7:250-6. https://doi.org/10.1001/jamacardio.2021.5083
  18. Langlois MR, Chapman MJ, Cobbaert C, Mora S, Remaley AT, Ros E, et al. Quantifying atherogenic lipoproteins: current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol. A consensus statement from EAS and EFLM. Clin Chem 2018;64:1006-33. https://doi.org/10.1373/clinchem.2018.287037
  19. Hong J, Gu H, Lee J, Lee W, Chun S, Han KH, et al. Intuitive modification of the Friedewald formula for calculation of LDL-cholesterol. Ann Lab Med 2023;43:29-37. https://doi.org/10.3343/alm.2023.43.1.29